Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Celgene has struck another long-term drug discovery deal with Evotec, a contract research firm in Hamburg, Germany. For an up-front payment of $65 million, Evotec will apply its phenotypic screening platform and compound libraries to discovering drugs for solid tumors. No details about milestone payments were disclosed. Celgene says it is pleased with a partnership it formed with Evotec in December 2016 in which it paid $45 million for neurodegenerative disease drug discovery.
This article has been sent to the following recipient: